HLA Alleles, Self-Peptides and Microbial Mimicry in SSc
SSc 中的 HLA 等位基因、自肽和微生物拟态
基本信息
- 批准号:6407027
- 负责人:
- 金额:$ 32.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-30 至 2006-05-31
- 项目状态:已结题
- 来源:
- 关键词:MHC class I antigen MHC class II antigen T lymphocyte alleles antigen presenting cell autoantigens biomimetics biotechnology cell cell interaction clinical research enzyme linked immunosorbent assay flow cytometry gene expression genetic polymorphism genetic susceptibility high performance liquid chromatography human genetic material tag human subject hybrid antibody immunoaffinity chromatography immunologic substance development /preparation monoclonal antibody pathologic process polymerase chain reaction synthetic antigens systemic scleroderma
项目摘要
DESCRIPTION (provided by applicant): The studies in this proposal test the
hypothesis that HLA alleles, HLA self-peptides and microbial mimicry, in
concert, contribute to the pathogenesis of systemic sclerosis (SSc).
Observations leading to the hypothesis point to a central role for the HLA-DRP
I molecule and are at least fourfold. The first is the finding that a woman's
risk of SSc is significantly increased by prior birth of a child who was
HLA-compatible for DRbeta1. Second, particular HLA alleles increase risk of
SSc, and include an amino acid sequence of the DR11 DRbeta1 chain (aa67-71,
"FLEDR") that is shared with DRbeta5. Third, human cytomegalovirus (HCMV) is
known to negatively impact conditions of chimerism that arise from
transplantation and spontaneously occurring microchimerism has recently been
implicated in SSc, as has HCMV. Finally, HCMV has sequence identity with a
conserved sequence of HLA-DRbeta1 (aa 53-57), that extends further (aa 53-58,
"LGRPDE") for DRB1 alleles that encode for DR11, which is associated with SSc.
The proposed experiments will provide the initial test of the concept that HLA
peptides derived from DRbeta1 function in cellular communications among host
cells and between host and non-host cells. The first Specific Aim will design
candidate peptides that encompass the identified sequences of the DRbeta1
molecule and will test them in binding and functional T cell assays. The second
and third Specific Aims will identify, enumerate and characterize peptide
specific T cells using artificial antigen presenting cells (aAPC) complexed
with the HLA self-peptides and peptides derived from the homologous HCMV
sequence. The aAPC is a very recently developed technique that offers an
advantage over tetramers in capturing low affinity interactions due to
permissive movement within a liposorne membrane. The aAPC will be used in a T
cell capture assay to isolate peptide specific T cells which will then be
phenotypically and functionally characterized in SSc patients and in controls.
Analysis will be conducted for cytokine production and differential gene
expression from sorted cells of SSc patients and controls. Finally, in the
fourth Specific Aim, Real-Time PCR will be used to quantitatively assess
microchimerism in peripheral blood mononuclear cell subsets from the same
patients and controls. The results of the proposed experiments will permit the
initial test of a model of pathogenesis that incorporates a concert of
contributory factors including specific HLA alleles, HLA-relationships among
host and non-host cells, and microbial mimicry in disease pathogenesis. Studies
are designed so as to maximize the potential to advance understanding of
disease pathogenesis in a way that could potentially lead to the development of
new therapeutic modalities for this difficult disease.
描述(由申请人提供):本提案中的研究测试了
假设HLA等位基因、HLA自身肽和微生物拟态,
协同作用,有助于系统性硬化症(SSc)的发病机制。
导致这一假设的观察结果指出HLA-DRP的核心作用
我分子和至少是四倍。第一个发现是,
患有SSc的风险会因之前出生的孩子而显着增加
DR β 1的HLA相容性。第二,特定的HLA等位基因增加了
SSc的氨基酸序列,并且包括DR 11 DR β 1链的氨基酸序列(aa 67 -71,
“FLEDR”),与DRbeta 5共享。第三,人巨细胞病毒(HCMV)是
已知对嵌合状态产生负面影响,
移植和自发发生的微嵌合体最近被
与SSc有关,HCMV也是如此。最后,HCMV与一种具有序列同一性的病毒具有序列同一性。
HLA-DR β 1的保守序列(aa 53-57),进一步延伸(aa 53-58,
“LGRPDE”),其用于编码与SSc相关的DR 11的DRB 1等位基因。
拟议的实验将提供初步测试的概念,HLA
来源于DR β 1的肽在宿主间的细胞通讯中起作用
细胞之间以及宿主和非宿主细胞之间。第一个具体目标将设计
包含DR β 1的鉴定序列的候选肽
分子,并将在结合和功能性T细胞测定中测试它们。第二
和第三个特定目标将识别,计数和表征肽
使用人工抗原递呈细胞(aAPC)复合的特异性T细胞
用HLA自身肽和来自同源HCMV的肽
顺序aAPC是一种最近开发的技术,
在捕获低亲和力相互作用方面优于四聚体,
允许在脂质体膜内移动。aAPC将用于T
细胞捕获测定以分离肽特异性T细胞,然后将其
在SSc患者和对照中的表型和功能特征。
将对细胞因子产生和差异基因进行分析
来自SSc患者和对照的分选细胞的表达。最后在
第四个特异性目的,实时PCR将用于定量评估
外周血单个核细胞亚群中的微嵌合体
患者和对照组。拟议实验的结果将允许
初步测试的发病机制模型,包括音乐会,
贡献因素包括特定的HLA等位基因,HLA之间的关系,
宿主和非宿主细胞,以及疾病发病机制中的微生物拟态。研究
旨在最大限度地提高对
疾病的发病机制,在某种程度上,可能会导致发展
新的治疗方法来治疗这一疑难病症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(4)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
J. Lee Nelson其他文献
Forward and reverse inheritance — the yin and the yang
正向和反向继承——阴与阳
- DOI:
10.1038/nrrheum.2017.88 - 发表时间:
2017-06-08 - 期刊:
- 影响因子:32.700
- 作者:
J. Lee Nelson;Nathalie C. Lambert - 通讯作者:
Nathalie C. Lambert
133: At diagnosis, total cell-free DNA concentration is elevated in preeclampsia versus controls
- DOI:
10.1016/j.ajog.2019.11.149 - 发表时间:
2020-01-01 - 期刊:
- 影响因子:
- 作者:
Teodora Kolarova;J. Lee Nelson;Hilary Gammill;Christina Lockwood;Raj Shree - 通讯作者:
Raj Shree
Microchimerism detection by human leucocyte antigen‐specific quantitative‐polymerase chain reaction analysis in recipients of allogeneic Epstein–Barr virus‐specific cytotoxic T lymphocytes
在同种异体 Epstein-Barr 病毒特异性细胞毒性 T 细胞淋巴受者中通过人白细胞抗原特异性定量聚合酶链反应分析检测微嵌合
- DOI:
10.1111/j.1365-2141.2005.05460.x - 发表时间:
2005 - 期刊:
- 影响因子:6.5
- 作者:
K. Lucas;J. Lee Nelson;Timothy D. Erickson;Qi Sun - 通讯作者:
Qi Sun
J. Lee Nelson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('J. Lee Nelson', 18)}}的其他基金
Transgenerational Microchimerism in Pregnancy Loss
妊娠失败中的跨代微嵌合现象
- 批准号:
7484075 - 财政年份:2007
- 资助金额:
$ 32.19万 - 项目类别:
Transgenerational Microchimerism in Pregnancy Loss
妊娠失败中的跨代微嵌合现象
- 批准号:
7306029 - 财政年份:2007
- 资助金额:
$ 32.19万 - 项目类别:
HLA Alleles, Self-Peptides and Microbial Mimicry in SSc
SSc 中的 HLA 等位基因、自肽和微生物拟态
- 批准号:
6607038 - 财政年份:2001
- 资助金额:
$ 32.19万 - 项目类别:
HLA Alleles, Self-Peptides and Microbial Mimicry in SSc
SSc 中的 HLA 等位基因、自肽和微生物拟态
- 批准号:
6760840 - 财政年份:2001
- 资助金额:
$ 32.19万 - 项目类别:
相似海外基金
MHC Class II Antigen Presentation In Melanoma: Impact on Immune Recognition
黑色素瘤中 MHC II 类抗原的呈现:对免疫识别的影响
- 批准号:
10674177 - 财政年份:2021
- 资助金额:
$ 32.19万 - 项目类别:
MHC class II antigen presentation in melanoma: impact on immune recognition
黑色素瘤中 MHC II 类抗原呈递:对免疫识别的影响
- 批准号:
10618790 - 财政年份:2021
- 资助金额:
$ 32.19万 - 项目类别:
MHC class II antigen presentation in melanoma: impact on immune recognition
黑色素瘤中 MHC II 类抗原呈递:对免疫识别的影响
- 批准号:
10392325 - 财政年份:2021
- 资助金额:
$ 32.19万 - 项目类别:
VARIATION IN MHC CLASS II ANTIGEN BINDING SITE OF ATLANTIC SALMON, SALMO SALAR
大西洋鲑鱼 SALMO SALAR MHC II 类抗原结合位点的变异
- 批准号:
8360306 - 财政年份:2011
- 资助金额:
$ 32.19万 - 项目类别:
VARIATION IN MHC CLASS II ANTIGEN BINDING SITE OF ATLANTIC SALMON, SALMO SALAR
大西洋鲑鱼 SALMO SALAR MHC II 类抗原结合位点的变异
- 批准号:
8167705 - 财政年份:2010
- 资助金额:
$ 32.19万 - 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
- 批准号:
8131116 - 财政年份:2007
- 资助金额:
$ 32.19万 - 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
- 批准号:
7321929 - 财政年份:2007
- 资助金额:
$ 32.19万 - 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
- 批准号:
7673392 - 财政年份:2007
- 资助金额:
$ 32.19万 - 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
- 批准号:
7483748 - 财政年份:2007
- 资助金额:
$ 32.19万 - 项目类别:
MHC Class II Antigen Processing and Immune Recognition of Melanoma
MHC II 类抗原加工和黑色素瘤的免疫识别
- 批准号:
7907767 - 财政年份:2007
- 资助金额:
$ 32.19万 - 项目类别: